

## **SAFETY DATA SHEETS**

**This SDS packet was issued with item:**

078920215

**The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).**

078920214

## Safety Data Sheet



### Section 1: Identification

#### Product identifier

- Product Name** • **Pentoxifylline tablet**
- Product Code** • NDC 68682-0101-10; NDC 68682-0101-50
- Product Description** • Prescription pharmaceutical product.

#### Relevant identified uses of the substance or mixture and uses advised against

- Recommended use** • Vasotec® is indicated for treatment of hypertension.
- Restrictions on use** • Refer to the product insert and/or prescribing information for restrictions on use and contraindications.

#### Details of the supplier of the safety data sheet

- Manufacturer** • Valeant Pharmaceuticals International, Inc.  
100 LifeSciences Parkway  
Steinbach R5G 1Z7  
Canada  
valeant.com
- Telephone (General)** • 1-800-321-4576
- Supplier** • Oceanside Pharmaceuticals, a division of Valeant Pharmaceuticals N. America, LLC  
400 Somerset Corporate Blvd.  
Bridgewater, NJ 08807  
United States  
valeant.com

#### Emergency telephone number

- Manufacturer** • 1-800-535-5053 - US - Infotrac
- Manufacturer** • +1 352-323-3500 - International - Infotrac

*This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to consumer use of the product.*

### Section 2: Hazard Identification

#### UN GHS

According to: UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

#### Classification of the substance or mixture

- UN GHS** • Acute Toxicity Oral 4  
Specific Target Organ Toxicity Single Exposure 1

#### Label elements

**UN GHS**

**DANGER**



**Hazard statements** • Harmful if swallowed  
Causes damage to organs - Blood

### Precautionary statements

- Prevention** • Do not handle until all safety precautions have been read and understood.  
Avoid breathing dust, fume, gas, mist, vapours and/or spray.  
Use personal protective equipment as required.  
Wash thoroughly after handling.
- Response** • IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.  
IF exposed or if you feel unwell: Call a POISON CENTER or doctor/physician.

**Storage/Disposal** • Store in a well-ventilated place. Keep container tightly closed.

### Other hazards

**UN GHS** • No data available

## Section 3 - Composition/Information on Ingredients

### Substances

- Material does not meet the criteria of a substance according to United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

### Mixtures

Composition			
Chemical Name	Identifiers	%	Classifications According to Regulation/Directive
Hydroxyethyl cellulose	CAS:9004-62-0	N/A	UN GHS: Skin Irrit. 2; Eye Irrit. 2A
Magnesium stearate	CAS:557-04-0 EINECS:209-150-3	N/A	UN GHS: NDA
Pentoxifylline	CAS:6493-05-6 EINECS:229-374-5	68.61%	UN GHS: NDA
Povidone	CAS:9003-39-8	N/A	UN GHS: NDA
Talc	CAS:14807-96-6 EINECS:238-877-9	N/A	UN GHS: Skin Irrit. 3; STOT RE 1

N/A - Designates that the chemical percentage of composition is not available as it is considered a trade secret.

## Section 4: First-Aid Measures

### Description of first aid measures

#### Inhalation

- Normal use of this product does not pose an inhalation hazard. However, during bulk handling should respiratory tract irritation develop, discontinue use and remove to fresh air. Get medical attention if irritation or other symptoms develop or persist.

#### Skin

- No specific treatment is necessary since this material is not likely to be hazardous by contact with the skin or mucous membranes. Immediately flush skin with large amounts of water. Remove contaminated clothing. If irritation (redness, rash, blistering) develops, get medical attention.

#### Eye

- IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,

if present and easy to do. Continue rinsing. Get medical attention immediately if symptoms occur.

#### Ingestion

- Obtain medical attention immediately if ingested.

#### Most important symptoms and effects, both acute and delayed

- Symptoms appear to be dose related. Symptoms usually occurred 4 to 5 hours after ingestion and lasted about 12 hours. Symptoms include: flushing, hypotension, convulsions, somnolence, loss of consciousness, fever, and agitation occurred.

#### Indication of any immediate medical attention and special treatment needed

##### Notes to Physician

- In addition to symptomatic treatment and gastric lavage, special attention must be given to supporting respiration, maintaining systemic blood pressure, and controlling convulsions. Activated charcoal has been used to absorb pentoxifylline in patients who have overdosed.

##### Antidotes

- The usual treatment for hypotension would be intravenous infusion of normal saline solution. Enalapril may be removed from general circulation by hemodialysis.

### Section 5: Fire-Fighting Measures

#### Extinguishing media

**Suitable Extinguishing Media** • Water spray, carbon dioxide, dry chemical powder or appropriate foam for surrounding fire.

**Unsuitable Extinguishing Media** • No data available

#### Special hazards arising from the substance or mixture

**Unusual Fire and Explosion Hazards** • No data available

**Hazardous Combustion Products** • No data available.

#### Advice for firefighters

- As in any fire, wear self-contained breathing apparatus and full protective gear to prevent contact with skin and eyes.

### Section 6 - Accidental Release Measures

#### Personal precautions, protective equipment and emergency procedures

**Personal Precautions** • No special controls or personal protection required under conditions of intended use. In the event of bulk spills, wear suitable protective eyewear, clothing, protective boots and protective gloves. Evacuate immediate area. Ensure adequate ventilation. Refer to Section 8.

**Emergency Procedures** • Keep unauthorized personnel away. Clean up spilled tablets and place in sealed container. Avoid breaking tablets or creating dust during clean up.

#### Environmental precautions

- No data available on the environmental impact of this product.

#### Methods and material for containment and cleaning up

**Containment/Clean-up Measures** • LARGE SPILLS: Use HEPA vacuum to clean up spill. If HEPA vacuum is not available, dampen spilled tablets with water prior to cleaning up to prevent dust cloud.

### Section 7 - Handling and Storage

#### Precautions for safe handling

**Handling** • Avoid breaking or crushing tablets. Minimize dust generation and accumulation. Use good safety and industrial hygiene practices.

## Conditions for safe storage, including any incompatibilities

### Storage

- Keep tightly closed. Store at controlled room temperature 25°C/77°F (excursions permitted to 15-30°C/59-86°F), to maintain product integrity. Use before date marked on carton and/or container. Protect from light.

## Section 8 - Exposure Controls/Personal Protection

### Control parameters

#### Exposure Limits/Guidelines

- Refer to the occupational exposure limits / guidelines for the individual product components.

Exposure Limits/Guidelines					
	Result	ACGIH	Canada Quebec	NIOSH	United States - New York
Talc (14807-96-6)	TWAs	2 mg/m <sup>3</sup> TWA (particulate matter containing no asbestos and <1% crystalline silica, respirable fraction)	3 mg/m <sup>3</sup> TWAEV (respirable dust)	2 mg/m <sup>3</sup> TWA (containing no Asbestos and <1% Quartz, respirable dust)	2 mg/m <sup>3</sup> TWA (containing no asbestos, respirable dust)

### Exposure Control Notations

#### ACGIH

- Talc (14807-96-6): **Carcinogens:** (A4 - Not Classifiable as a Human Carcinogen (containing no asbestos fibers))

### Exposure Limits Supplemental

#### OSHA

- Talc (14807-96-6): **Mineral Dusts:** (20 mppcf TWA (if 1% Quartz or more, use Quartz limit))

#### ACGIH

- Talc (14807-96-6): **TLV Basis - Critical Effects:** (pulmonary fibrosis (containing no asbestos fibers); pulmonary function (containing no asbestos fibers))

## Exposure controls

### Engineering

#### Measures/Controls

- NO SPECIAL CONTROLS ARE REQUIRED UNDER CONDITIONS OF INTENDED USE. Local exhaust ventilation should be provided when handling bulk product.

### Personal Protective Equipment

#### Respiratory

- For bulk handling, the personal breathing protection should be determined based upon a risk assessment and in accordance with local regulations. Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or symptoms are experienced.

#### Eye/Face

- Wear protective eyewear (goggles, face shield, or safety glasses) when handling bulk product before closed in final packaging.

#### Hands

- Wear protective gloves when handling bulk product before closed in final packaging.

#### Skin/Body

- Avoid contact with skin.

### General Industrial Hygiene Considerations

- Handle in accordance with good industrial hygiene and safety practice. Wash thoroughly with soap and water after handling.

### Environmental Exposure Controls

- No data available

## Section 9 - Physical and Chemical Properties

### Information on Physical and Chemical Properties

Material Description			
Physical Form	Solid	Appearance/Description	white, oblong compressed tablet.
Color	White	Odor	No odor.
Odor Threshold	Not relevant		
General Properties			
Boiling Point	No data available	Melting Point/Freezing Point	No data available
Decomposition Temperature	No data available	pH	Not relevant
Specific Gravity/Relative Density	No data available	Water Solubility	Soluble
Viscosity	Not relevant		
Volatility			
Vapor Pressure	Not relevant	Vapor Density	Not relevant
Evaporation Rate	Not relevant		
Flammability			
Flash Point	Not relevant	UEL	Not relevant
LEL	Not relevant	Autoignition	Not relevant
Flammability (solid, gas)	Not relevant		
Environmental			
Octanol/Water Partition coefficient	No data available		

## Section 10: Stability and Reactivity

### Reactivity

- Stable under normal temperatures and pressures.

### Chemical stability

- Hazardous polymerization will not occur.

### Possibility of hazardous reactions

- No data available

### Conditions to avoid

- Excessive heat or moisture.

### Incompatible materials

- Strong oxidizing agents.

### Hazardous decomposition products

- Nitrous oxides. Irritating and/or toxic fumes or gases.

## Section 11 - Toxicological Information

### Information on toxicological effects

Components		
Pentoxifylline (68.61%)	6493-05-6	<b>Acute Toxicity:</b> Ingestion/Oral-Mouse LD50 • 1225 mg/kg; Ingestion/Oral-Rat LD50 • 1170 mg/kg; <b>Behavioral:</b> Changes in motor activity (specific assay); Lungs, Thorax, or Respiration: <b>Respiratory depression</b>

GHS Properties	Classification
Acute toxicity	UN GHS • Acute Toxicity - Oral 4
Skin corrosion/Irritation	UN GHS • Classification criteria not met

Serious eye damage/Irritation	UN GHS • Classification criteria not met
Skin sensitization	UN GHS • Classification criteria not met
Respiratory sensitization	UN GHS • Classification criteria not met
Aspiration Hazard	UN GHS • Classification criteria not met
Carcinogenicity	UN GHS • Classification criteria not met
Germ Cell Mutagenicity	UN GHS • Classification criteria not met
Toxicity for Reproduction	UN GHS • Classification criteria not met
STOT-SE	UN GHS • Specific Target Organ Toxicity Single Exposure 1
STOT-RE	UN GHS • Classification criteria not met

**Target Organs**

- Blood

**Potential Health Effects****Inhalation****Acute (Immediate)**

- Under normal conditions of use, no health effects are expected. Exposure to dust from broken tablets may cause irritation.

**Chronic (Delayed)**

- Repeated and prolonged exposure may cause irritation.

**Skin****Acute (Immediate)**

- Under normal conditions of use, no health effects are expected.

**Chronic (Delayed)**

- Repeated and prolonged exposure may cause irritation.

**Eye****Acute (Immediate)**

- May cause mild eye irritation with direct contact to eye.

**Chronic (Delayed)**

- Under normal conditions of use, no health effects are expected.

**Ingestion****Acute (Immediate)**

- Blood thinner which in doses exceeding prescription level increase risk of hemorrhage. Toxic if ingested in excess of prescription dose.

**Chronic (Delayed)**

- No data available

Carcinogenic Effects			
	CAS	IARC	NTP
Povidone	9003-39-8	Group 3-Not Classifiable	Not Listed
Talc	14807-96-6	Group 3-Not Classifiable	Evidence of Carcinogenicity

**Section 12 - Ecological Information****Toxicity**

- This material has not been tested for environmental effects.

**Persistence and degradability**

- No data available

**Bioaccumulative potential**

- No data available

**Mobility in Soil**

- No data available

**Other adverse effects**

## Section 13 - Disposal Considerations

### Waste treatment methods

#### Product waste

- Waste characterizations and compliance with applicable laws are the responsibility solely of the waste generator.

#### Packaging waste

- Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.

## Section 14 - Transport Information

	UN number	UN proper shipping name	Transport hazard class (es)	Packing group	Environmental hazards
DOT	Not Applicable	Not Regulated	Not Applicable	Not Applicable	
TDG	Not Applicable	Not Regulated	Not Applicable	Not Applicable	
IMO/IMDG	Not Applicable	Not Regulated	Not Applicable	Not Applicable	
IATA/ICAO	Not Applicable	Not Regulated	Not Applicable	Not Applicable	

**Special precautions for user** • No data available

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code** • No data available

## Section 15 - Regulatory Information

### Safety, health and environmental regulations/legislation specific for the substance or mixture

**SARA Hazard Classifications** • No data available

Inventory				
Component	CAS	Canada DSL	EU EINECS	TSCA
Hydroxyethyl cellulose	9004-62-0	Yes	No	Yes
Povidone	9003-39-8	Yes	No	Yes
Magnesium stearate	557-04-0	Yes	Yes	Yes
Talc	14807-96-6	Yes	Yes	Yes
Pentoxifylline	6493-05-6	No	Yes	No

### Canada

#### Labor

##### Canada - WHMIS - Classifications of Substances

• Magnesium stearate	557-04-0	Not Listed
• Talc	14807-96-6	D2A
• Hydroxyethyl cellulose	9004-62-0	Uncontrolled product according to WHMIS classification criteria
• Pentoxifylline	6493-05-6	Not Listed
• Povidone	9003-39-8	Uncontrolled product according to WHMIS classification criteria (listed under Povidone)



## United States - California

### Environment

#### U.S. - California - Proposition 65 - Carcinogens List

• Magnesium stearate	557-04-0	Not Listed
• Talc	14807-96-6	Not Listed
• Hydroxyethyl cellulose	9004-62-0	Not Listed
• Pentoxifylline	6493-05-6	Not Listed
• Povidone	9003-39-8	Not Listed

#### U.S. - California - Proposition 65 - Developmental Toxicity

• Magnesium stearate	557-04-0	Not Listed
• Talc	14807-96-6	Not Listed
• Hydroxyethyl cellulose	9004-62-0	Not Listed
• Pentoxifylline	6493-05-6	Not Listed
• Povidone	9003-39-8	Not Listed

#### U.S. - California - Proposition 65 - Reproductive Toxicity - Female

• Magnesium stearate	557-04-0	Not Listed
• Talc	14807-96-6	Not Listed
• Hydroxyethyl cellulose	9004-62-0	Not Listed
• Pentoxifylline	6493-05-6	Not Listed
• Povidone	9003-39-8	Not Listed

#### U.S. - California - Proposition 65 - Reproductive Toxicity - Male

• Magnesium stearate	557-04-0	Not Listed
• Talc	14807-96-6	Not Listed
• Hydroxyethyl cellulose	9004-62-0	Not Listed
• Pentoxifylline	6493-05-6	Not Listed
• Povidone	9003-39-8	Not Listed

## Section 16 - Other Information

**Revision Date** • 22/February/2016

**Last Revision Date** • 22/February/2016

**Preparation Date** • 22/February/2016

**Disclaimer/Statement of Liability** • To the best of our knowledge, the information contained herein is accurate. However, neither Valeant Pharmaceuticals International, Inc. nor any of its subsidiaries assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. NO WARRANTY, EXPRESS OR IMPLIED, OF MERCHANTABILITY, FITNESS OR OTHERWISE IS MADE. In no event shall Valeant Pharmaceuticals International, Inc. or any of its subsidiaries be liable for any special, incidental or consequential damages.